A Phase 3 clinical trial evaluating two digital therapeutics for the treatment of experiential negative symptoms of Schizophrenia reached its primary completion on 2025-06-20, having enrolled 464 participants.
Background
Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by a range of symptoms, often categorized as positive (e.g., hallucinations, delusions), negative (e.g., blunted affect, anhedonia, alogia), and cognitive (e.g., impaired memory, executive function). Experiential negative symptoms, such as anhedonia (inability to experience pleasure) and avolition (lack of motivation), are particularly challenging to treat and can significantly impact a patient's functional recovery and quality of life. Current treatments primarily focus on managing positive symptoms, with fewer effective options for negative symptoms. Digital therapeutics offer a novel approach to complement standard care by providing accessible, evidence-based interventions that can be delivered directly to patients.
Trial design
This Phase 3 study enrolled 464 participants with Schizophrenia. The trial's primary objective was to evaluate the efficacy of two prescription digital therapeutics (PDT) when used in addition to standard of care (SOC) therapy. These interventions targeted the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults. The study design aimed to assess how these digital tools could complement existing treatments for this challenging aspect of the condition.
What this means
The primary completion of this Phase 3 trial signifies a significant milestone in the evaluation of digital therapeutics for schizophrenia. While specific efficacy or safety data are not yet available, the completion indicates that the study has progressed through its main data collection phase for its primary endpoint. The focus on experiential negative symptoms, a difficult-to-treat aspect of schizophrenia, highlights an area of unmet medical need. The involvement of two prescription digital therapeutics suggests an innovative approach to complement standard care, potentially offering new avenues for improving patient outcomes and quality of life for individuals living with schizophrenia, particularly concerning their motivation and ability to experience pleasure. Future release of results will clarify the impact of these digital interventions.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for the study NCT05838625, titled "Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia", was posted on 2025-06-20 on clinicaltrials.gov.